Form 8-K - Current report:
SEC Accession No. 0001437749-25-015514
Filing Date
2025-05-08
Accepted
2025-05-08 16:20:43
Documents
15
Period of Report
2025-05-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K pbyi20250303_8k.htm   iXBRL 8-K 25441
2 EXHIBIT 99.1 ex_785138.htm EX-99.1 152875
  Complete submission text file 0001437749-25-015514.txt   335505

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA pbyi-20250508.xsd EX-101.SCH 3578
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE pbyi-20250508_def.xml EX-101.DEF 11806
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE pbyi-20250508_lab.xml EX-101.LAB 15857
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pbyi-20250508_pre.xml EX-101.PRE 12021
17 EXTRACTED XBRL INSTANCE DOCUMENT pbyi20250303_8k_htm.xml XML 2944
Mailing Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024
Business Address 10880 WILSHIRE BLVD. SUITE 2150 LOS ANGELES CA 90024 (424) 248-6500
PUMA BIOTECHNOLOGY, INC. (Filer) CIK: 0001401667 (see all company filings)

EIN.: 770683487 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35703 | Film No.: 25926534
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)